Search Results

European customers can now subscribe to Sino Biological’s newsletter to receive a special gift and unlock access to EliteScience benefits.

Advancing efficiency and alignment in biologics development, through product-specific methods, to support broader availability of biologics, including biosimilars, for patients

In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.

A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicine for approval.

As biologics, biosimilars and GLP-1s drive demand for sterile drug products, CMOs and CDMOs are investing in fill-finish, lyophilization, inspection and packaging capacity to keep pace with a dynamic injectable market.

With PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.

Expands Latin America presence with strategic partnership with Mobil Saúde and builds on TempraMed’s recently granted Brazilian patent portfolio Highlights: TempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world’s largest markets for diabetes, GLP-1 therapies, and temperature-sensitive biologics1. Diabetes market alone reached USD $2.15 Billion in 2025 Partnership builds on TempraMed’s recently granted Brazilian patent protecting the VIVI Box™ platform Expands TempraMed’s commercialization footprint across Latin America following recent regional expansion initiatives